The DOI matches its Crossref record.
Neoadjuvant Clinical Trial With Sorafenib for Patients With Stage II or Higher Renal Cell Carcinoma
Open accessAbstract
Purpose: The multitargeted tyrosine kinase inhibitor sorafenib is used for the treatment of advanced-stage renal cell carcinoma. However, the safety and efficacy of this agent have yet to be evaluated in the preoperative period, where there may be potential advantages including tumor downstaging. This prospective trial evaluates the safety and feasibility of sorafenib in the preoperative setting. Patients and Methods: Thirty patients with clinical stage II or higher renal masses, selected based on their candidacy for nephrectomy, underwent preoperative treatment with sorafenib. Toxicities, surgical complications, and tumor responses were monitored. Results: Of the thirty patients enrolled, 17 patients had localized disease and 13 had metastatic disease. After a course of sorafenib therapy (median duration, 33 days), a decrease in primary tumor size (median, 9.6%) and radiographic evidence of loss of intratumoral enhancement, quantified using a methodology similar to Choi criteria (median, 13%), was also observed. According to Response Evaluation Criteria in Solid Tumors, of the 28 patients evaluable for response, two patients had a partial response and 26 had stable disease, with no patients progressing on therapy. Toxicities from sorafenib were similar to that expected with this class of medication. All patients were able to proceed with nephrectomy and no surgical complications related to sorafenib administration were observed. Conclusion: The administration of preoperative sorafenib therapy can impact the size and density of the primary tumor and appears safe and feasible. Further studies are required to determine if preoperative systemic therapy improves outcomes in patients undergoing nephrectomy for renal cell carcinoma.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Jonasch, E., Gao, J., & Rathmell, W. K. (2014) · BMJ · doi:10.1136/bmj.g4797 · Cited by 636
Self-citationSurvival after complete surgical resection of multiple metastases from renal cell carcinoma
Alt, A. L., Boorjian, S. A., Lohse, C. M., Costello, B. A., Leibovich, B. C., & Blute, M. L. (2011) · Cancer · doi:10.1002/cncr.25836 · Cited by 426
Virumbrales-Muñoz, M., Chen, J., Ayuso, J., Lee, M., Abel, E. J., & Beebe, D. J. (2020) · Lab on a Chip · doi:10.1039/d0lc00252f · Cited by 39
Metadata
- Authors
- Cowey, C. L., Amin, C., Pruthi, R. S., Wallen, E. M., Nielsen, M. E., Grigson, G., Watkins, C., Nance, K. V., Crane, J., Jalkut, M., Moore, D. T., Kim, W. Y., Godley, P. A., Whang, Y. E., Fielding, J. R., & Rathmell, W. K.
- Venue
- Journal of Clinical Oncology
- Published
- 2010-03-20
- Volume
- 28
- Issue
- 9
- Pages
- 1502-1507
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2125174117
- Cited by
- 199
- References
- 0
- FWCI
- 23.37
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Neoadjuvant Clinical Trial With Sorafenib for Patients With Stage II or Higher Renal Cell Carcinoma. https://app.cochat.ai/papers/10.1200/jco.2009.24.7759
- The paper
- Cowey, C. L., Amin, C., Pruthi, R. S., Wallen, E. M., Nielsen, M. E., Grigson, G., Watkins, C., Nance, K. V., Crane, J., Jalkut, M., Moore, D. T., Kim, W. Y., Godley, P. A., Whang, Y. E., Fielding, J. R., & Rathmell, W. K. (2010). Neoadjuvant Clinical Trial With Sorafenib for Patients With Stage II or Higher Renal Cell Carcinoma. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2009.24.7759
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.